Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-hodgkin lymphoma

Overview of attention for article published in Clinical Therapeutics, January 2009

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 7 news outlets

patent: 2 patents

Readers on

mendeley: 111 Mendeley

So far, Altmetric has seen 7 news stories from 7 outlets.

Accord Healthcare Adds Generic Drug for Use in Treating Leukemia and Non-Hodgkin's Lymphoma

Ticker Tech, 07 Dec 2022

Bendamustine Lyo. Injection joins Accord's portfolio of chemotherapy drugs DURHAM, N.C., Dec.

Accord Healthcare Adds Generic Drug for Use in Treating Leukemia and Non-Hodgkin's Lymphoma

Yahoo! Finance USA, 07 Dec 2022

Bendamustine Lyo. Injection joins Accord's portfolio of chemotherapy drugs DURHAM, N.C., Dec.

Accord Healthcare Adds Generic Drug for Use in Treating Leukemia and Non-Hodgkin's Lymphoma

Morning Star, 07 Dec 2022

Accord Healthcare Adds Generic Drug for Use in Treating Leukemia and Non-Hodgkin's Lymphoma PR Newswire DURHAM, N.C., Dec.

Accord Healthcare Adds Generic Drug for Use in Treating Leukemia and Non-Hodgkin's Lymphoma

Benzinga, 07 Dec 2022

Bendamustine Lyo. Injection joins Accord's portfolio of chemotherapy drugs DURHAM, N.C., Dec.

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 3 additional news stories.